News from thoratec corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 27, 2015, 16:00 ET HeartMate 3™ CE-zulassungsstudie erreicht primären endpunkt

Zu den Höhepunkten zählen die beste 6-Monate-Überlebensrate in einer klinischen LVAD/CE-Zulassungsstudie und die niedrige Inzidenz...


Sep 27, 2015, 16:00 ET L'évaluation du marquage CE du HeartMate 3™ passe le critère principal d'évaluation

Les points forts comprennent le meilleur taux de survie enregistré lors d'un essai clinique de marquage CE portant sur un appareil...


Sep 27, 2015, 16:00 ET HeartMate 3™ CE Mark Trial Meets Primary Endpoint

 Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts,...


Sep 14, 2015, 08:45 ET Thoratec Issues Voluntary Device Correction

Thoratec Corporation (NASDAQ: THOR) today issued a voluntary Urgent Medical Device Correction Letter to all hospitals who have patients supported...


Sep 04, 2015, 08:30 ET Thoratec Announces Start Of Shield II™ U.S. Clinical Trial

 Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts,...


Aug 21, 2015, 08:45 ET Thoratec Announces End Of "Go Shop" Period

Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts,...


Aug 04, 2015, 16:02 ET Thoratec® Reports Second Quarter 2015 Results

 Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support (MCS) therapies to save, support and restore failing...


May 26, 2015, 16:25 ET Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast

Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, said...


May 26, 2015, 09:00 ET Thoratec Receives Conditional FDA Approval For The Shield II U.S. Clinical Trial For HeartMate PHP

Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts,...


May 07, 2015, 16:02 ET Thoratec® Reports First Quarter 2015 Results

 Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support (MCS) therapies to save, support and restore failing...


May 01, 2015, 09:00 ET Thoratec Announces Addition To Senior Management Team

 Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts,...


Apr 30, 2015, 16:20 ET Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast

 Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts,...


Apr 20, 2015, 09:10 ET Thoratec Schedules First Quarter Conference Call, Webcast

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing...


Apr 17, 2015, 03:30 ET ROADMAP Study Demonstrates HeartMate II® Benefits In Ambulatory Advanced Heart Failure Patients

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing...


Apr 16, 2015, 09:49 ET Thoratec Comments On HeartMate II® Data In ENDURANCE Destination Therapy Trial

 Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore...


Apr 06, 2015, 08:45 ET Thoratec To Webcast Investor Meeting At ISHLT Conference

 Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore...


Apr 02, 2015, 09:00 ET Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III™ U.S. IDE Clinical Trial

 Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore...


Feb 25, 2015, 08:45 ET Thoratec Announces Presentations At Investor Conferences For March 2015

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing...


Feb 10, 2015, 16:02 ET Thoratec® Reports Fourth Quarter 2014 Results

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing...


Aug 29, 2014, 14:47 ET Thoratec Presentation At Morgan Stanley Healthcare Conference To Be Webcast

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing...


Aug 06, 2014, 16:02 ET Thoratec Announces $30 Million Accelerated Share Repurchase

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing...


Aug 06, 2014, 16:02 ET Thoratec Announces Start Of The HeartMate PHP™ CE Mark Trial

Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts,...


Aug 06, 2014, 16:02 ET Thoratec® Reports Second Quarter 2014 Results

 Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore...


Aug 04, 2014, 17:11 ET Thoratec Presentation At Canaccord Genuity Growth Conference To Be Webcast

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing...


May 06, 2014, 16:02 ET Thoratec® Reports First Quarter 2014 Results

 Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and...